Since the aforementioned loss of p16INK4a is a common feature of KRAS-driven PC, the inhibition of CDK4/6 has gained substantial interest as a potential therapeutic reatment for p16INK4a-deficient tumours. This evidence concerns the gene KRAS and pachyonychia congenita.